Selva Therapeutics
Manufacturing · United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.selvarx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Selva Therapeutics
Selva Therapeutics is a biotechnology company focused on developing therapeutics for infectious diseases, notably their lead drug candidate SLV213, which is an antiviral therapy capable of combatting a variety of viral infections including COVID-19, Ebola, and Chagas disease. The company aims to provide effective treatments that protect global health by rapidly advancing SLV213 through clinical trials. This oral drug is designed for outpatient use, offering a preferred treatment option for mild to moderate infections. Selva Therapeutics continues to research SLV213's broad-spectrum efficacy against multiple infectious diseases while emphasizing its unique mechanism of action.Explore more
Selva Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Selva Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Selva Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Selva Therapeutics
Product Launch: Get notified when Selva Therapeutics launches new products
Earning: See what the market has to say on Selva Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Selva Therapeutics has new funding data
Check if Selva Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Selva Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Selva Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Selva Therapeutics
Find more new buyers
Compare Similar Companies to Selva Therapeutics
Compare insights from companies similar to Selva Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Selva Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Selva Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Selva Therapeutics.
Selva Therapeutics financials insights
Gather financial insights about Selva Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$3M
Selva Therapeutics Tech Stack
A closer look at the technologies used by Selva Therapeutics
See more technologies
Selva Therapeutics News & Media
Selva to Present Preclinical Data at ASV 2021 Demonstrating Prophylactic and Therapeutic Oral Dosing of SLV213 for COVID-19 Protected Lungs from SARS-CoV-2-Induced Damage
SAN DIEGO--(BUSINESS WIRE)-- #ASV2021--Selva's Preclinical Data Demonstrate Prophylactic and Therapeutic Oral Dosing of SLV213 for COVID-19 Protected Lungs from SARS-CoV-2-Induced DamageSelva Announces SLV213, a Potential Oral COVID-19 Treatment, Has Broad Activity Against SARS-CoV-2 Variants of Concern
SAN DIEGO--(BUSINESS WIRE)-- #COVID19--Selva Announces SLV213, a Potential Oral COVID-19 Treatment, Has Broad Activity Against SARS-CoV-2 Variants of ConcernSelva Therapeutics Announces Successful Completion of Phase 1 Clinical Study of SLV213, a Potential Oral Treatment for COVID-19
SAN DIEGO--(BUSINESS WIRE)-- #COVID19--Selva's Phase 1 clinical study met its primary objective of demonstrating safety and tolerability of SLV213, a potential oral treatment for COVID-19.Selva Therapeutics Announces First Dosing in Phase 1 Clinical Study of SLV213, a Potential Oral Treatment for COVID-19
SAN DIEGO--(BUSINESS WIRE)-- #COVID19--Selva has received FDA clearance of an IND application for SLV213 for the treatment of COVID-19 and has dosed the first subjects in a Phase 1 study.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Selva Therapeutics
Sign Up For FreeTo access detailed company insights
Selva Therapeutics is a biotechnology company focused on developing therapeutics for infectious diseases, notably their lead drug candidate SLV213, which is an antiviral therapy capable of combatting a variety of viral infections including COVID-19, Ebola, and Chagas disease. The company aims to provide effective treatments that protect global heal... Read More
